Top Markets
Coin of the day
BioAge Labs Inc. BioAge Labs Inc.

BioAge Labs Inc.

BIOA
Rang in aandelen #15401
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops... BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Aandeelprijs
$9.50
Marktkapitalisatie
$357.67M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
92.70%
Land
US
Handel BioAge Labs Inc. (BIOA)

Categorie

P/B-ratio voor BioAge Labs Inc. (BIOA)
P/B-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van BioAge Labs Inc. is de huidige P/B-ratio (TTM) 0. Eind 2026 had het bedrijf een P/B-ratio van 0.
P/B-ratiohistoriek voor BioAge Labs Inc. van 2026 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/B-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/B-ratio Verschil in P/B-ratio Land
6.828 -
US
7.5116 -
NL
8.2199 -
US
3.9942 -
AU
- -
CH